Rising Cannabis Legalization And Wellness Trends Will Fuel Expansion

AnalystHighTarget

Not Invested

Community Contributor

Published

10 Aug 25

AnalystHighTarget's Fair Value

CA$3.25

43.1% undervalued

10 Sep

CA$1.85

-15.9%

-8.0%

-15.9%

-8.0%

You can edit this narrative until Aug 10 10:13 PM. Then, changes will post as Updates.

Author's Valuation

CA$3.2543.1% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$3.25

43.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.26%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.61%

Calculation

US$6.58m

Earnings '28

164.65x

PE Ratio '28

US$1.08b

Market Cap '28

US$1.08b

Market Cap '28

380.14m

No. shares '28

US$2.85

Share Price '28

US$2.85 Share Price '28

Discounted to 2025 @ 6.70% p.a.

US$2.35

Fair Value '25

US$2.35 Fair Value '25

Converted to CAD @ 1.3864 USD/CAD Exchange Rate

CA$3.26

Fair Value '25